Back

Abbott Laboratories

Ticker: ABT ISIN: US0028241000
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer Trading above 200-day average
Market cap
$154.15B
P/E
24.79
Forward P/E
16.53
Profit margin
13.90%
Revenue growth QoQ
7.80%
Div. yield
2.69%
Beta
0.62
$116.13 -0.46%
Price as of 2026-08-25 · NYSE

Performance by timeframe

Rolling returns
1 Month +11.14%
6 Months +2.55%
1 Year -9.71%
5 Years +0.54% p.a.+2.73%
10 Years +12.49% p.a.+224.14%
Since inception +9.55% p.a.+874.83%
Calendar year returns
YTD -5.59%
2025 +12.87%
2024 +4.82%
2023 +2.26%
2022 -20.68%
2021 +30.53%

Key stats

Market cap
154.15B
P/E
24.79
Dividend yield
2.69%
Beta
0.62
52-week range
81.97 - 136.28
50-day MA
90.43
200-day MA
113.85
Section 1

Business overview

Company profile data from fundamentals.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Sector Healthcare
Industry Medical Devices
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 12.33%
ROA 5.59%
Profit margin 13.90%
Operating margin 13.47%
PEG ratio 1.34
Revenue/share TTM 25.91
Revenue TTM 45.13B
EBITDA 11.74B
Gross profit TTM 25.50B
Beta 0.62

Valuation

Trailing P/E 24.79
Forward P/E 16.53
P/B 3.03
P/S 3.42
EV/EBITDA 15.60
EV/Revenue 4.09

ESG Scores

Total ESG 32.4
Environment 4.0
Social 20.7
Governance 13.2
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 5.48
Quarterly earnings growth -19.70%
Revenue TTM 45.13B
Reported quarters 129
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 2.69%
Forward annual div. yield 1.75%
Dividend per share 2.4400
Payout ratio 53.70%
Ex-dividend date 2025-07-15
Next dividend date 2026-08-17
Split factor 10000:4798
Last split date 2013-01-02
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $142.48
Analyst rating 4.1071

Ownership & short interest

Shares outstanding 1.74B
Shares float 1.73B
Institutional ownership 80.78%
Insider ownership 54.30%
Short ratio 1.73
Short % of float 1.41%

Details

Instrument metadata and source update timestamps.

Symbol ABT
Name Abbott Laboratories
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US0028241000
Country USA
Code + exchange ABT.NYSE
Last price date 2026-06-17
Fundamentals updated 2026-06-18

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.